The U.S. Viral Vector CDMO Market is projected to reach USD 2.75 Billion by 2035, while Europe is expected to reach USD 1.93 Billion.

Austin, United States, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The Viral Vector CDMO Market Size was valued at USD 1.29 Billion in 2025 and is projected to reach USD 7.04 Billion by 2035, growing at a CAGR of 18.55% during 2026–2035, according to a new report by SNS Insider. Increasing demand for viral vectors manufacturing, gene therapy, cell therapy manufacturing, and contract biopharmaceutical manufacturing is driving the growth of the market around the globe.

The market for viral vector CDMOs is showing promise since there is an increasing tendency for biotech and pharma firms to seek out specialists to help them in developing and manufacturing processes and performing analytics, clinical, commercial, and regulatory activities. The increasing difficulty in producing the various forms of AAV, lentiviral, and other viral vectors is also contributing to this trend.

Download the Viral Vector CDMO Market Sample Report: https://www.snsinsider.com/sample-request/10507

Gene Therapy Manufacturing and CDMO Outsourcing Support Viral Vector Market Growth

The growing pipeline of gene and cell therapies is driving an increased need for customized viral vector development and manufacturing solutions. Biotech and pharma companies have started relying more on process development, testing, and manufacturing through contract manufacturing organizations that are skilled and scalable. Funding into AAV/lentivirus vector technologies, suspension cell cultures, disposable bioprocessing, analytical testing, and digital biomanufacturing will likely present more opportunities in the Viral Vector CDMO Market.

Viral Vector CDMO Market Key Takeaways

• Leading Vector Type: Adeno-Associated Virus (AAV) (~38.00% share).
• Leading Service Type: Clinical Manufacturing (~31.00% share).
• Leading Application: Gene Therapy (~43.00% share).
• Leading End User: Biotechnology Companies (~39.00% share).
• Largest Regional Market: North America (~47.00% share).
• Fastest-Growing Regional Market: Asia Pacific (23.46% CAGR).

North America Leads the Viral Vector CDMO Market While Asia Pacific Registers the Fastest Growth

North America held an approximate market share of 47.00% in 2025 in terms of revenue share owing to a well-developed biotechnology sector, high level of gene therapy development activities, good manufacturing facilities, and substantial investments in research and development. The USA continues to contribute the major portion in terms of demand and manufacturing of viral vectors.

The U.S. Viral Vector CDMO Market was valued at approximately USD 0.56 Billion in 2025 and is projected to reach USD 2.75 Billion by 2035, growing at a CAGR of 17.22%. The U.S. accounted for approximately 93.00% of the North American market in 2025, due to its well-established biotechnology sector, advanced clinical research facilities, increasing pipeline of gene therapies, and availability of CDMO service providers.

The Europe Viral Vector CDMO Market was valued at USD 0.36 Billion in 2025 and is projected to reach USD 1.93 Billion by 2035, growing at a CAGR of 18.28%. The market growth will be propelled by the well-established biopharmaceutical sector, research capabilities, and commercialization of advanced therapies in the region.

The Asia Pacific region is anticipated to record the highest CAGR of 23.46% over the forecast period from 2026 to 2035. This is driven by increasing biotechnology industries, growth in governmental initiatives for therapeutic drugs, and capacity to manufacture biologics and viral vectors. Some key countries in the region include China, Japan, South Korea, Singapore, and India.

Viral Vector CDMO Market Segmentation Analysis

By Vector Type: Adeno-associated virus (AAV) was the leading segment of the market, holding a market share of around 38.00% in 2025 due to its wide-ranging use in gene therapies for treatment of rare genetic diseases, inherited retinal diseases, neuromuscular disorders, and central nervous system diseases. Lentiviral Vectors is anticipated to witness the highest growth rate with a CAGR of 19.37% due to the growing use in CAR-T cell therapy and hematopoietic stem cell therapy.

By Service Type: Clinical Manufacturing dominated the market share at about 31.00% in 2025 as a result of the rise in the number of gene and cell therapy candidates entering the phase I, phase II, and phase III clinical trials. The Commercial Manufacturing segment is forecasted to grow at the fastest CAGR of 23.46% due to the increase in the commercialization of approved gene therapies and the demand for large-scale production of viral vectors.

By Application: The market share of Gene Therapy was at its highest at 43.00% in 2025 owing to the rising development of therapeutics for rare genetic conditions, oncology, ophthalmology, neurological disorders, and other diseases. The Vaccines application is likely to witness the fastest growth in terms of CAGR with 23.69% owing to the rising demand for viral vector-based vaccines.

By End User: The Biotechnology Companies occupied the largest market share of about 39.00% in 2025 as biotechnology companies are among the primary producers of gene therapies, cell therapies, and viral vectors which usually require specialized CDMOs due to lack of production capabilities within the company. The fastest growing segment of end users is likely to be the Government Organizations segment at a rate of 21.90% driven by increasing investment in biologics manufacturing and biotechnology advancements.

Explore the Complete Viral Vector CDMO Market Report: https://www.snsinsider.com/reports/viral-vector-cdmo-market-10507

Leading Market Players Listed in this Report are:

• Thermo Fisher Scientific Inc.
• Catalent Inc.
• Lonza Group AG
• FUJIFILM Diosynth Biotechnologies
• Charles River Laboratories International, Inc.
• WuXi Advanced Therapies
• Oxford Biomedica plc
• AGC Biologics
• Viralgen Vector Core
• Forge Biologics
• SK pharmteco
• YPOSKESI
• Genezen Laboratories
• Cognate BioServices
• Batavia Biosciences
• Cobra Biologics
• Cell and Gene Therapy Catapult
• Kaneka Eurogentec S.A.
• Miltenyi Biotec
• Andelyn Biosciences

Recent Developments:

• 2026: Thermo Fisher Scientific expanded its viral vector manufacturing capabilities through investments in advanced GMP production facilities to support increasing commercial demand for gene and cell therapies.
• 2026: Catalent strengthened its viral vector CDMO portfolio by expanding commercial manufacturing capacity and implementing advanced automated bioprocessing technologies for scalable gene therapy production.

Exclusive Insights Available in the Viral Vector CDMO Market Report

• Viral Vector Manufacturing Capacity Analysis – evaluates production capacity, expansion strategies, and regional manufacturing capabilities across leading CDMOs.
• Gene and Cell Therapy Pipeline Metrics – analyzes the relationship between expanding therapeutic pipelines and demand for AAV and lentiviral vector manufacturing.
• CDMO Outsourcing and Service Demand Analysis – examines outsourcing trends across process development, analytical testing, clinical manufacturing, and commercial-scale production.
• Commercial Manufacturing Expansion Tracker – identifies capacity investments and emerging opportunities as gene therapies transition from clinical development to commercialization.
• Regional Biomanufacturing Investment Analysis – evaluates manufacturing investments and biotechnology infrastructure across North America, Europe, and Asia Pacific.
• Competitive Manufacturing Landscape – assesses major viral vector CDMOs based on service capabilities, vector expertise, manufacturing scale, and geographic presence.

Buy the Viral Vector CDMO Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/10507

Viral Vector CDMO Market Report Scope

Frequently Asked Questions (FAQs):

What was the Viral Vector CDMO Market size in 2025?

The market was valued at USD 1.29 Billion in 2025.

What is the projected Viral Vector CDMO Market size by 2035?

The market is projected to reach USD 7.04 Billion by 2035.

What is the CAGR of the Viral Vector CDMO Market?

The market is projected to grow at a CAGR of 18.55% during 2026–2035.

Which region dominated the Viral Vector CDMO Market in 2025?

North America dominated the market with approximately 47.00% revenue share.

Which vector type held the largest market share?

Adeno-Associated Virus (AAV) accounted for approximately 38.00% of the market in 2025.

Related Market Reports

Viral Vectors and Plasmid DNA Manufacturing Market Size 2026

Viral Vector Manufacturing Market Growth 2026

Cell and Gene Therapy CDMO Market Outlook 2026

Viral Vector Production Research Use Market Trends 2026

Cell & Gene Therapy Manufacturing Services Market Growth 2026

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com